283 related articles for article (PubMed ID: 9387950)
1. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N
Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749
[TBL] [Abstract][Full Text] [Related]
3. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
4. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.
Am J Respir Crit Care Med; 1998 Jul; 158(1):49-59. PubMed ID: 9655706
[TBL] [Abstract][Full Text] [Related]
5. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ).
Piitulainen E; Eriksson S
Eur Respir J; 1999 Feb; 13(2):247-51. PubMed ID: 10065663
[TBL] [Abstract][Full Text] [Related]
6. [Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Pneumologie; 1998 Oct; 52(10):545-52. PubMed ID: 9847632
[TBL] [Abstract][Full Text] [Related]
7. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis.
Chapman KR; Stockley RA; Dawkins C; Wilkes MM; Navickis RJ
COPD; 2009 Jun; 6(3):177-84. PubMed ID: 19811373
[TBL] [Abstract][Full Text] [Related]
8. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
Sclar DA; Evans MA; Robison LM; Skaer TL
Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
[TBL] [Abstract][Full Text] [Related]
9. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society.
Abboud RT; Ford GT; Chapman KR;
Can Respir J; 2001; 8(2):81-8. PubMed ID: 11320399
[TBL] [Abstract][Full Text] [Related]
10. Alpha1-antitrypsin augmentation therapy.
Pierce JA
Chest; 1997 Oct; 112(4):872-4. PubMed ID: 9377947
[No Abstract] [Full Text] [Related]
11. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.
Wencker M; Fuhrmann B; Banik N; Konietzko N;
Chest; 2001 Mar; 119(3):737-44. PubMed ID: 11243951
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group.
Schluchter MD; Stoller JK; Barker AF; Buist AS; Crystal RG; Donohue JF; Fallat RJ; Turino GM; Vreim CE; Wu MC
Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):796-801. PubMed ID: 10712324
[TBL] [Abstract][Full Text] [Related]
13. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
Dirksen A; Dijkman JH; Madsen F; Stoel B; Hutchison DC; Ulrik CS; Skovgaard LT; Kok-Jensen A; Rudolphus A; Seersholm N; Vrooman HA; Reiber JH; Hansen NC; Heckscher T; Viskum K; Stolk J
Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1468-72. PubMed ID: 10556107
[TBL] [Abstract][Full Text] [Related]
15. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
16. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough.
Balbi B; Ferrarotti I; Miravitlles M
Eur Respir J; 2016 Jan; 47(1):35-8. PubMed ID: 26721962
[No Abstract] [Full Text] [Related]
17. Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ.
Seersholm N; Kok-Jensen A; Dirksen A
Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):1922-5. PubMed ID: 8520756
[TBL] [Abstract][Full Text] [Related]
18. alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding.
Stoller JK; Aboussouan LS
Thorax; 2004 Aug; 59(8):708-12. PubMed ID: 15282394
[TBL] [Abstract][Full Text] [Related]
19. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.
Dawkins PA; Dawkins CL; Wood AM; Nightingale PG; Stockley JA; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1338-44. PubMed ID: 19164359
[TBL] [Abstract][Full Text] [Related]
20. α1-Antitrypsin Deficiency.
Hatipoğlu U; Stoller JK
Clin Chest Med; 2016 Sep; 37(3):487-504. PubMed ID: 27514595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]